Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Isis Pharma shares hit all-time high

December 11, 2014 – 5:54 pm | Edit Post

Shares of the Carlsbad biotech reached $65.13 intraday, closed at $61.87

Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy With FDA

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, a biotechnology company focusing on developing therapies that target the Achilles Heel of Cancer: the tumor blood vessels, announced today the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead immune therapy, ValloVax. Once the IND is approved, Batu Biologics will proceed with a Phase I/II clinical…

Regen BioPharma Presented Novel Therapeutic Target For Leukemia And Myelodysplastic Syndrome At The American Society of Hematology Annual Meeting

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – December 11, 2014) – Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new…

Obese Children’s Brains More Responsive To Sugar, University of California, San Diego (UCSD) Study

December 11, 2014 – 5:00 pm | Edit Post

Obese Children’s Brains More Responsive To Sugar A new study led by researchers at University of California, San Diego School of Medicine finds that the brains of obese children literally light up differently when tasting sugar.Published online in International Journal of Obesity, the study does not show a causal relationship between sugar hypersensitivity…

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Announces Pricing Of Public Offering Of Common Stock

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 12, 2014 /PRNewswire/ –MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of

Halozyme Therapeutics, Inc. Announces Presentations Of Preclinical Data At The

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 12, 2014 /PRNewswire/ –Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical…

Obese Kids’ Brains Crave For Sugar, University of California, San Diego (UCSD) Study

December 11, 2014 – 5:00 pm | Edit Post

Obese Children’s Brains More Responsive To Sugar A new study led by researchers at University of California, San Diego School of Medicine finds that the brains of obese children literally light up differently when tasting sugar.Published online in International Journal of Obesity, the study does not show a causal relationship between sugar hypersensitivity…

Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy With FDA

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, a biotechnology company focusing on developing therapies that target the Achilles Heel of Cancer: the tumor blood vessels, announced today the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead immune therapy, ValloVax. Once the IND is approved, Batu Biologics will proceed with a Phase I/II clinical…

Batu Biologics Files Investigational Drug App With FDA

December 11, 2014 – 3:51 pm | Edit Post

Batu Biologics Inc., a biotechnology company developing a cancer vaccine that targets a tumor’s blood vessels, announced the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead immune therapy, ValloVax.

Startup applies to test cancer therapy

December 11, 2014 – 3:27 pm | Edit Post

Batu Biologics to try vaccine in non-small cell lung cancer.